BTG plc announced that the FDA has approved Varithena (polidocanol injectable foam) for the treatment of patients with incompetent veins and visible varicosities of the great saphenous vein (GSV) ...

BTG plc (LSE: BTG), the specialist healthcare company, today announces that the US Food and Drug Administration (FDA) has approved Varithena(TM) (polidocanol injectable foam) for the treatment of ...

WEST CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--BTG plc (LSE:BTG), the specialist healthcare company, announced that the U.S. Food and Drug Administration has approved an extension of the post-activation ...

BOTHELL, WA, April 29, 2019 /PRNewswire/ -- BTG plc (LSE: BTG), the global specialist healthcare company, today highlighted the VIEW VLU Registry interim study results, presented at the International ...

The US Food and Drug Administration (FDA) has approved polidocanol injectable foam (Varithena, BTG) for the treatment of incompetent veins and visible varicosities of the great saphenous vein (GSV) ...

British pharmaceutical firm BTG said U.S. regulators had approved its varicose vein treatment that uses an injectable foam to dissolve the veins as an alternative to surgical removal. Varithena, ...

Ten years after BTG weathered a tempest as the FDA erected a barrier to its new treatment for varicose veins, the British biotech company has finally gained U.S. approval for its product and ...

Q: I heard that there is a new treatment option for varicose veins. Can you describe Varithena, and how do I know if it is right for me? A: Varithena, a prescription medicine, is used as a minimally ...

LONDON, Nov 26 (Reuters) - British pharmaceutical firm BTG said U.S. regulators had approved its groundbreaking varicose veins treatment that uses an injectable foam to dissolve the veins as an ...

LONDON (Reuters) - British pharmaceutical firm BTG said U.S. regulators had approved its varicose vein treatment that uses an injectable foam to dissolve the veins as an alternative to surgical ...